| Abstract [eng] |
The objective of the study – is to determine the most characteristic of acute promyelocytic leukemia blasts biomarker expression features. To achieve this objective there has been assigned the following tasks: Applying Flow cytometry method to find out the most typical promyelocytic leukemia immunophenotype markers; identify the most typical blast immunophenotype of acute promyelocytic leukemia; identify the most sensitive and most specific immunophenotype for acute promyeloytic leukemia To fulfill the Objective and Tasks we examined 64 patients who were suspected of acute promyelocytic leukemia. All of these individuals have been treated in Santariškės Vilnius University Hospital Department of Hematology in years 2008-2015. This study analyzed patient`s data such as gender, age, complete blood count. Extremely important for the study was patient`s data: blast biomarkers expression - assesed by a flow cytometer, cytomorphological patient`s bone marrow or peripheral blood analysis and molecular genetics data on presence or absence of mutations, which have resulted in acute promyelocytic leukemia. The obtained results showed that for acute promyelocytic leukemia the most typical biomarkers combinations are: a negative HLA-DR, CD34 biomarkers expression, low CD56 marker expression, positive CD117 marker expression and high CD64 sign expression at mutations between 15 and 17 chromosomes couples; research has revealed 4 typical acute promyelocytic leukemia immunofenotypes: SSC-h / CD34- / CD117 + b / CD33 ++ / CD13 + h / CD2- / CD56- / CD64 + / CD15 + b / HLA-DR-; SSC-h / CD34- / CD117 + b / CD33 ++ / CD13 ++ / CD2- / CD56- / CD64 + / CD15 + b / HLA-DR-; SSC-h / CD34- / CD117 + / CD33 + / CD13 + / CD2 + b / CD56- / CD64 + b / CD15 + b / HLA-DR-; SSC-H / CD34- / CD117 + / CD33 ++ / CD13 ++ / CD2 + b / CD56- / CD64 + / CD15- / HLA-DR-; the most sensitive phenotypes of them were SSC-h / CD34- / CD117 + b / CD33 ++ / CD13 + h / CD2- / CD56- / CD64 + / CD15 + b / HLA-DR-; SSC-h / CD34- / CD117+ b / CD33 ++ / CD13 ++ / CD2- / CD56- / CD64 + / CD15 + b / HLA-DR- and SSC-H / CD34- / CD117 + / CD33 ++ / CD13 ++ / CD2 + b / CD56 - / CD64 + / CD15- / HLA-DR-. |
